Thermo Fisher Scientific, Inc. - TMO STOCK NEWS

Thermo Fisher Scientific has announced its acquisition of PPD for $47.50 per share, totaling $17.4 billion plus $3.5 billion in net debt. This deal represents a 24% premium to PPD's stock price as of April 13, 2021. PPD, a leader in the $50 billion clinical research services industry, generated $4.7 billion in revenue in 2020. The transaction is expected to close by the end of 2021 and will enhance Thermo Fisher's services to the pharma and biotech sectors, with projected cost synergies of $125 million by year three.

Thermo Fisher Scientific Inc. (NYSE:TMO) has received Emergency Use Authorization (EUA) from the FDA for its Amplitude Solution with the TaqPath COVID-19 High-Throughput Combo Kit. This system allows laboratories to conduct up to 8,000 PCR tests daily with minimal staffing. The Amplitude Solution combines Thermo Fisher's technologies and is already implemented in labs globally, including Europe and Japan. Although COVID-19 cases are decreasing, demand for routine testing remains, reinforcing the system's relevance. The solution is aimed at scaling testing capacity amidst ongoing pandemic challenges.

Thermo Fisher Scientific (NYSE: TMO) will announce its Q1 2021 financial results before the market opens on April 29, 2021. The company will host a conference call at 8:30 a.m. EDT to discuss its financial performance and future expectations. The call can be accessed at (833) 714-0931 within the U.S. and (778) 560-2662 internationally, with conference ID 7956359. For further details, visit www.thermofisher.com. Annual revenue exceeds $30 billion, emphasizing its leadership in the science sector.

Thermo Fisher Scientific (NYSE:TMO) has launched the Thermo Scientific AerosolSense Sampler, a new surveillance tool for rapid detection of in-air pathogens, including SARS-CoV-2. This device collects aerosol samples from ambient air, enabling subsequent laboratory analysis through PCR testing. Mark Stevenson, COO, emphasized the need for reliable solutions in various institutions to ensure safety amid ongoing pandemic risks. The AerosolSense Sampler aims to enhance monitoring capabilities while supporting decision makers in hospitals and other facilities.

Thermo Fisher Scientific (NYSE:TMO) announced over $600 million in investments to expand its bioprocessing production capabilities through 2022. This expansion aims to more than double manufacturing capacity to support biopharma customers during COVID-19 and future vaccine developments. The investment will create over 1,500 jobs across 11 sites in the Americas, Europe, and Asia. Key areas of expansion include single-use technologies, purification resins, and cell culture media production, enhancing supply chain resilience and customer support.

Thermo Fisher Scientific (NYSE: TMO) has finalized its acquisition of Mesa Biotech, enhancing its point-of-care molecular diagnostics capabilities. The Accula System, developed by Mesa, allows rapid, accurate testing for COVID-19 and other diseases, providing results in just 30 minutes. This strategic move is expected to generate approximately $200 million in revenue for Thermo Fisher in 2021. The acquisition aims to leverage Thermo Fisher's resources with Mesa's innovative technology, positioning the company to meet the growing demand for point-of-care diagnostics globally.

Thermo Fisher Scientific (NYSE: TMO) will be represented by CEO Marc N. Casper at the 41st Annual Cowen Healthcare Conference on March 3, 2021, at 10:20 a.m. EDT. The event will be held virtually, and interested parties can access the presentation through the company's website. With annual revenues exceeding $30 billion, Thermo Fisher Scientific is a leading provider of scientific services and products, aiming to make the world healthier, cleaner, and safer.

Thermo Fisher Scientific (NYSE: TMO) announced a quarterly cash dividend of $0.26 per common share, reflecting an 18% increase from the prior $0.22 payment. The dividend is payable on April 16, 2021, to shareholders of record by March 16, 2021. With annual revenues exceeding $30 billion, Thermo Fisher continues to lead in serving scientific needs globally, supporting research and improving diagnostics through its renowned brands.

Thermo Fisher Scientific (NYSE:TMO) has acquired cell sorting technology assets from Propel Labs, enhancing its Biosciences business. This includes the Bigfoot Spectral Cell Sorter, which offers advanced sorting capabilities and faster throughput. Approximately 40 employees from Propel Labs will join Thermo Fisher, while Propel will continue operating independently. The Bigfoot technology aims to meet growing demands in cell and gene therapies, addressing significant challenges in cytometry analysis. Thermo Fisher's annual revenue exceeds $30 billion, positioning it well to improve healthcare outcomes.